NOS2 and myeloid sarcoma: Although iNOS inhibitors have shown some efficacy in slowing disease in EAE, a model for Multiple Sclerosis (MS), induction of EAE in iNOS−/− mice led to a higher incidence and severity of disease, when compared to WT mice, that was characterized by an inability of iNOS−/− mice to undergo disease remission [35,36,37,38].